Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Survival of a probiotic-containing product using capsule-within-capsule technology in an in vitro model of the stomach and small intestine (TIM-1)
in Beneficial MicrobesSearch for other papers by K. Venema in
Current site
Google Scholar
Search for other papers by J. Verhoeven in
Current site
Google Scholar
Search for other papers by C. Beckman in
Current site
Google Scholar
Search for other papers by D. Keller in
Current site
Google Scholar
The aim of the research was to compare the survival of a blend of five probiotic strains (2 bifidobacteria and 3 lactobacilli) in a capsule within capsule (Duocap®) containing Ahiflower® oil, as compared to the strains in the powder (with or without Ahiflower oil), or the strains when present in the inner capsule only. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM-1), simulating human adults. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains after transit through the gastric compartment in the Duocap capsule was higher by about a factor of 1.5 compared to the other 3 variables. In these gastric experiments, the Ahiflower oil did not seem to have an additional benefit, in the sense that it did not increase survival over the strains alone. After transit through the complete gastrointestinal tract survival was approximately 2-fold higher for the strains within the Duocap capsule, compared to the strains within the inner capsule or the powder. In these experiments, Ahiflower oil did have an additional benefit. The survival of the strains in the combination of powder with Ahiflower oil showed a similar survival as that of the Duocap, although in the first few hours of the experiments survival of both species lagged behind, and only caught up at the end of the test. In conclusion, the developed capsule-in-capsule technology increased the amount of viable cells in the upper gastrointestinal tract, mainly due to the presence of the polyunsaturated fatty acids contained in the outer capsule, which particularly protected the blend of probiotics in the small intestine.
-
Blanquet-Diot, S., Denis, S., Chalancon, S., Chaira, F., Cardot, J.M. and Alric, M., 2012. Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans. Pharmaceutical Research 29: 1444-1453. https://doi.org/10.1007/s11095-011-0620-5
-
Campana, R., van Hemert, S. and Baffone, W., 2017. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathogens 9: 12. https://doi.org/10.1186/s13099-017-0162-4
-
Eiberger, I., Bley, H., Molimard, P., Maathuis, A. and Venema, K., 2011. Evaluation of the appropriate galenical technology for the site specific delivery of probiotic bacteria. In: Renaud, A.-C. (ed.) Proceedings of the Congrés Vitagora, Dijon, France. Propulse, Dijon, France, p. vii.
'Evaluation of the appropriate galenical technology for the site specific delivery of probiotic bacteria', ().
-
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2001. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Available at: http://tinyurl.com/8bccc3r.
-
Hatanaka, M., Nakamura, Y., Maathuis, A.J., Venema, K., Murota, I. and Yamamoto, N., 2012. Influence of Bacillus subtilis C-3102 on microbiota in a dynamic in vitro model of the gastrointestinal tract simulating human conditions. Benefical Microbes 3: 229-236. https://doi.org/10.3920/BM2012.0016
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
-
Keller, D., Van Dinter, R., Cash, H., Farmer, S. and Venema, K., 2017. Bacillus coagulans GBI-30, 6086 increases plant protein digestion in a dynamic, computer-controlled in vitro model of the small intestine (TIM-1). Beneficial Microbes 8: 491-496. https://doi.org/10.3920/BM2016.0196
-
Larsen, N., Cahu, T.B., Isay Saad, S.M., Blennow, A. and Jespersen, L., 2018. The effect of pectins on survival of probiotic Lactobacillus spp. in gastrointestinal juices is related to their structure and physical properties. Food Microbiology 74: 11-20. https://doi.org/10.1016/j.fm.2018.02.015
-
Marteau, P., Minekus, M., Havenaar, R. and Huis in ‘t Veld, J.H., 1997. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. Journal of Dairy Science 80: 1031-1037. https://doi.org/10.3168/jds.S0022-0302(97)76027-2
-
Martinez, R.C., Aynaou, A.E., Albrecht, S., Schols, H.A., De Martinis, E.C., Zoetendal, E.G. Venema, K., Saad, S.M. and Smidt, H., 2011. In vitro evaluation of gastrointestinal survival of Lactobacillus amylovorus DSM 16698 alone and combined with galactooligosaccharides, milk and/or Bifidobacterium animalis subsp. lactis Bb-12. International Journal of Food Microbiology 149: 152-158. https://doi.org/10.1016/j.ijfoodmicro.2011.06.010
-
Minekus, M., 2015. The TNO gastro-intestinal model (TIM). In: Verhoeckx, K., Cotter, P., Lopez-Exposito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D. and Wichers, H. (eds.) The impact of food bioactives on health: in vitro and ex vivo models. Springer, Cham, Switzerland, pp. 37-46. https://doi.org/10.1007/978-3-319-16104-4_5
-
Minekus, M., Marteau, P., Havenaar, R. and Huis In’t Veld, J.H.J., 1995. A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine. Alternatives to Laboratory Animals 23: 197-209.
'A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine ' () 23 Alternatives to Laboratory Animals : 197 -209.
-
Surono, I., Verhoeven, J., Verbruggen, S. and Venema, K., 2018. Microencapsulation increases survival of the probiotic Lactobacillus plantarum IS-10506, but not Enterococcus faecium IS-27526 in a dynamic, computer-controlled in vitro model of the upper gastrointestinal tract. Journal of Applied Microbiology 124: 1604-1609. https://doi.org/10.1111/jam.13740
-
Venema, K., 2015. Synbiotics: more than just the sum of pro-and prebiotics? In: Venema, K. and do Carmo, A.P. (eds.) Probiotics and prebiotics: current research and future trends. Caister Academic Press, Poole, UK, pp. 345-360. https://doi.org/10.21775/9781910190098
-
Venema, K., Verhoeven, J., Verbruggen, S., Espinosa, L. and Courau, S., 2019. Probiotic survival during a multi-layered tablet development as tested in a dynamic, computer-controlled in vitro model of the stomach and small intestine (TIM-1). Letters in Applied Microbiology 69: 325-332. https://doi.org/10.1111/lam.13211
Supplementary Materials
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 703 | 249 | 23 |
| PDF-Downloads | 910 | 318 | 13 |
Survival of a probiotic-containing product using capsule-within-capsule technology in an in vitro model of the stomach and small intestine (TIM-1)
in Beneficial MicrobesSearch for other papers by K. Venema in
Current site
Google Scholar
PubMed
Search for other papers by J. Verhoeven in
Current site
Google Scholar
PubMed
Search for other papers by C. Beckman in
Current site
Google Scholar
PubMed
Search for other papers by D. Keller in
Current site
Google Scholar
PubMed
The aim of the research was to compare the survival of a blend of five probiotic strains (2 bifidobacteria and 3 lactobacilli) in a capsule within capsule (Duocap®) containing Ahiflower® oil, as compared to the strains in the powder (with or without Ahiflower oil), or the strains when present in the inner capsule only. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM-1), simulating human adults. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains after transit through the gastric compartment in the Duocap capsule was higher by about a factor of 1.5 compared to the other 3 variables. In these gastric experiments, the Ahiflower oil did not seem to have an additional benefit, in the sense that it did not increase survival over the strains alone. After transit through the complete gastrointestinal tract survival was approximately 2-fold higher for the strains within the Duocap capsule, compared to the strains within the inner capsule or the powder. In these experiments, Ahiflower oil did have an additional benefit. The survival of the strains in the combination of powder with Ahiflower oil showed a similar survival as that of the Duocap, although in the first few hours of the experiments survival of both species lagged behind, and only caught up at the end of the test. In conclusion, the developed capsule-in-capsule technology increased the amount of viable cells in the upper gastrointestinal tract, mainly due to the presence of the polyunsaturated fatty acids contained in the outer capsule, which particularly protected the blend of probiotics in the small intestine.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 703 | 249 | 23 |
| PDF-Downloads | 910 | 318 | 13 |
